Here is my calculation of the value of the value of our franking credit balance (on the basis that it would be used to provide a fully franked dividend(s) to all shareholders.
Number of Shares on Issue: approx 568M (maybe 590M if all performance rights vest)
Franking Credit balance: $21.3M (note 24 to accounts)
Franking Credit balance (FCB) per share: 3.75cps
Dividend which can be fully franked (at 30% tax rate) using this FCB: 8.75cps
Cash required by company to pay this dividend: $49.7M
Grossed-up value of this dividend to shareholders: 12.5 cps
So to be able to pay this dividend to all shareholders and so use and exhaust the valuable (to shareholders) franking credit balance, HGO needs to have both $49.7M in cash plus the ability to fund its ongoing business.
Note that all profits over the next two years (at least) will not incur tax as HGO has $223M of accumulated losses to use (note 24).
It is going to be interesting to see what means and timing that directors can find to distribute this to shareholders - but for me fully franked divs to all holders is fairest, and asap is the correct timing.
- Forums
- ASX - By Stock
- HGO
- HGO Position
HGO Position, page-52
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add HGO (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.3¢ |
Change
-0.001(1.35%) |
Mkt cap ! $152.9M |
Open | High | Low | Value | Volume |
7.4¢ | 7.5¢ | 7.3¢ | $239.0K | 3.265M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 69444 | 7.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.5¢ | 801465 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 69444 | 0.073 |
5 | 393790 | 0.072 |
1 | 400000 | 0.071 |
8 | 292155 | 0.070 |
3 | 388840 | 0.069 |
Price($) | Vol. | No. |
---|---|---|
0.075 | 801465 | 7 |
0.076 | 145130 | 2 |
0.077 | 38999 | 2 |
0.078 | 392305 | 4 |
0.079 | 336136 | 4 |
Last trade - 15.00pm 15/07/2024 (20 minute delay) ? |
Featured News
HGO (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online